Current and future therapy of invasive fungal infections

Current Clinical Topics in Infectious Diseases

Volumn , Issue 18, 1998, Pages 19-36

  Andriole, Vincent T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; DRUG CARRIER; FLUCYTOSINE; LIPOSOME; TRIAZOLE DERIVATIVE;

HUMAN; MYCOSIS; REVIEW;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG CARRIERS; FLUCYTOSINE; HUMANS; LIPOSOMES; MYCOSES; TRIAZOLES;

EID: 0031608468     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (63)

1. Anaissie EJ. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992;14(Suppl 1):43-53.
2. Pfaller MA, Wenzel R. The impact of changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992; 11:287-291.
3. Richardson MD. Opportunistic and pathogenic fungi. J Antimicrob Ag Chemother 1991; 28(Suppl A):1-11.
4. Walsh TJ. Invasive fungal infections: problems and challenges in developing new antifungal compounds. In: Sutcliffe J, Georgopapadakou NH, eds. Emerging targets in antibacterial and antifungal chemotherapy. New York: Chapman & Hall, 1992:349-373.
5. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Ant Ag Chemother 1996; 279-291.
6. Beck-Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the U.S. J Infect Dis 1993;167: 1247-1251.
7. Denning DW. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Ag Chemother 1991;28(Suppl B):1-6.
8. Diamond RD. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Rev Infect Dis 1991; 13:480-486.
9. Vazquez JA, Sanchez V, Dmuchowski C, Dembry LM, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis 1993;168: 195-201.
10. Bodey GP. Antifungal agents. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis and treatment. New York: Raven Press, 1993:371-406.
11. Andriole VT, Bodey GP, eds. Pocket guide to systemic antifungal therapy. New Jersey: Scientific Therapeutics, 1994.
12. Current WL, Tang J, Boylan C, Watson P, Zeckner D, Turner W, Rodriguez M, Dixon C, Ma D, Radding JA. Glucan biosynthesis as a target for antifungal: the echinocandin class of antifungal agents. In: Dixon GK, Copping LG, Hollomon DW, eds. Antifungal agents: discovery and mode. BIOS Scientific Publishers, 1995:143-160.
13. Graybill JR. The future of antifungal therapy. Clin Infect Dis 1996;22(Suppl 2):166-178.
14. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochem Biophy Acta 1986;864: 257-304.
15. Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother 1991;28(Suppl B):27-38.
16. Hazen E, Brown R. Two antifungal agents produced by a soil actinomycete. Science 1950;112:423.
17. Hazen E, Brown R. Fungicidin, an antibiotic produced by a soil actinomycete. Proc Soc Exp Biol 1951;76:93.
18. Bennett JE. Developing drugs for the deep mycoses: a short history. In: Bennett JE, Hay RJ, Peterson PK, eds. New strategies in fungal disease. London: Churchill Livingstone, 1992: 3-12.
19. Gold W. Amphotericins A and B: antifungal antibiotic produced by streptomycete. I. In vitro studies. Antibiot Ann 1955-56:579-586.
20. Andriole VT, Kravetz HM. The use of amphotericin B in man. JAMA 1962;180:269-272.
21. Vandeputte J, Wachtel JL, Stiller ET. Amphotericins A and B: antifungal antibiotics produced by streptomycete. II. Isolation and properties of crystalline amphotericins. Antibiot Ann 1955-56:587-591.
22. Dutcher JD. Chemical studies of amphotericin B. I. Preparation of hydrogenation product and isolation of mycosamine and acetolysis products. Antibio Ann 1956-57: 866-869.
23. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-329.
24. Gallis HA. Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Clin Infect Dis 1996;22(Suppl 2):145-147.
25. Kravetz HM, Andriole VT, Huber MA, Utz JP. Oral administration of solubilized amphotericin B. N Engl J Med 1961;265:183-184.
26. Bodey GP. Antifungal agents. In: Andriole VT, ed. Current ID drugs. Philadelphia: Current Medicine, 1996:229-248.
27. Pilot Study. Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Transplantation 1991;51:925-927.
28. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22(Suppl 2):133-144.
29. Lopez-Berestein G, Bodey GP, Fainstein V, Keating M, Frankel LS, Zeluff B, Gentry L, Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989;149:2533-2536.
30. Kline S, Larsen TA, Fieber L, Fishbach R, Greenwood M, Harris R, Kline MW, Tennican PO, Janoff EN. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infect Dis 1995;21:1154-1158.
31. Janknegt R, Van Etten EWM, de Marie S. Lipid formulations of amphotericin B. Curr Opinion ID 1996;9:403-406.
32. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-1153.
33. Bowden EA, Cays M, Gooley T, Mamelok RD, van Burik J. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-1215.
34. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococeal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-321.
35. Wingard JE. Conventional versus lipid formulations of amphotericin B. In: Anaissie EJ, Rinaldi MG, chairmen. Focus on Fungal Infections, VII. San Antonio, Texas, March 12-14, 1997, 33.
36. Joly V, Aubry P, Ndayiragide A, et al. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or intra-lipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996;23:556-562.
37. Grunberg E, Titsworth E, Bennett M. Chemotherapeutic activity of 5-fluorocytosine. Antimicrob Ag Chemother 1964:556.
38. Sonne LJ. Flucytosine to counter systemic mycoses. Drug Therapy 1978:55-63.
39. Plempel M, Bartmann K, Buchel KH, Regel E. First clinical experience in systemic mycoses with a new oral broad spectrum antimycotic. Deutsche Medizinische Wochenschrift 1969; 94:1356.
40. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-1330.
41. Anaissie EHJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-972.
42. Kauffman CA. Role of azoles in antifungal therapy. Clin Infect Dis 1996;22(Suppl 2):148-153.
43. Czwerwiec FS, Bilsker MS, Kamerman ML, et al. Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis. Am J Med 1993;94:545-546.
44. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-89.
45. 3: demonstration of efficacy in a prospective, multicenter trial. Clin Infect Dis 1996;23:1282-1286.
46. Galgianai JN, Catanzasro AN, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993;119:28-35.
47. McKinsey DS, Kauffman CA, Pappas PG, et al. Fluconazole therapy for histoplasmosis. Clin Infect Dis 1996;23:996-1001.
48. Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis 1995;20: 267-271.
49. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851.
50. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. Ann Intern Med 1997;126:689-696.
51. Kauffman CA. Newer developments in therapy for endemic mycoses. Clin Infect Dis 1994;19(Suppl 1):28-32.
52. George D, Miniter P, Andriole VT. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Ag Chemother 1996;40:86-91.
53. Troke PF, Brammer KW, Hitchcock CA, Yonren S, Sarantis N. UK-109496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC). In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995: abstract F73.
54. Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Ag Chemother 1996;40:1910-1913.
55. Hata K, Kimura J, Miki H, et al. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Ag Chemother 1996;40: 2237-2242.
56. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob Ag Chemother 1995;39:1077-1081.
57. Smith JG, Abruzzo GK, Gill CJ, et al. Evaluation of pneumocandin L-743872 in neutropenic mouse models of disseminated candidiasis and aspergillosis. In: Programs and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996: abstract F41.
58. Najvar L, Graybill J, Montalbo E, Barchiesi F, Luther M. Evaluation of L-743,872 (872) in the treatment of murine histoplasmosis. In: Programs and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996: abstract F43.
59. Li RK, Fothergill AW, Rinaldi MG. In vitro antifungal activity of SP-920704 in combination with fluconazole and itraconazole. In: Programs and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996: abstract F189.
60. Flores ME, Hector RF. In vitro activity of the antifungal nikkomycin Z (SP-920704) in combination with fluconazole or itraconazole vs. yeasts. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996: abstract F190.
61. Ryder NS, Leitner I. Activity of terbinafine against Aspergillus in vitro, in combination with amphotericin B or triazoles. In: Programs and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996: abstract E54.
62. Ryder NS, Wagner S, Leitner I. In vitro activity of terbinafine against Candida and other yeasts by the NCCLS method. In: Programs and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996: abstract E55.
63. Rodero L, Vitale R, Hochenfellner F, Canteros C, Davel G. In vitro activity of terbinafine in combination with triazole drugs against fluconazole resistant candida species. In: Programs and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996: abstract E56.